Navigation Links
Monogram Announces Conference Call
Date:10/23/2008

LEADING HIV PHYSICIAN, Dr. DAVID HARDY, TO DISCUSS CLINICAL USE OF THE TROFILE(TM) ASSAY AND SELZENTRY(TM) IN CONJUNCTION WITH THE THIRD QUARTER

2008 FINANCIAL RESULTS CONFERENCE CALL

SOUTH SAN FRANCISCO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc., (Nasdaq: MGRM) announced that it will hold a conference call on Monday, October 27, 2008 at 4:30 p.m. (Eastern Time) to discuss the clinical use of Monogram's Trofile(TM) Assay in conjunction with Pfizer's CCR5 antagonist, Selzentry(TM). Monogram will also review its third quarter 2008 financial results. The call will be hosted by William D. Young, Chairman & CEO of Monogram. Dr. David Hardy will participate in the call. Dr. Hardy is Director, Division of Infectious Diseases at Cedars-Sinai Medical Center and is Associate Professor of Medicine-in-Residence at the David Geffen School of Medicine at UCLA.

To participate in the live teleconference, please call (877) 604-9672, or (719) 325-4896 for international callers, fifteen minutes before the conference begins. Live audio of the call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. Access to live and archived audio of the conference call will be available on the Investor Relations section at http://www.monogrambio.com. Following the live broadcast, a replay of the call will also be available at (888) 203-1112 or (719) 457-0820 for international callers, through Sunday, November 9, 2008. The replay passcode is 4461917. The information provided on the teleconference is only accurate at the time of the conference call, and Monogram will take no responsibility for providing updated information except as required by law.

About Monogram Biosciences, Inc.

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com.

Trofile is a trademark of Monogram Biosciences, Inc. Selzentry is a trademark of Pfizer Inc.

contacts: Alfred G. Merriweather Jeremiah Hall

Chief Financial Officer Feinstein Kean Healthcare

Tel: 650 624-4576 Tel: 415 677-2700

amerriweather@monogrambio.com jeremiah.hall@fkhealth.com


'/>"/>
SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Monogram Receives NASDAQ Notification
2. Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer
3. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
4. Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
5. Monogram Biosciences Announces Second Quarter 2008 Financial Results Conference Call
6. Monogram Biosciences to Present at the Collins Stewart Fourth Annual Growth Conference
7. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
8. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
9. Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
10. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
11. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Park Systems , a leader ... for all SPIE attendees and Park customers on Feb. 27, 2017 ... the San Jose Convention Center. The luncheon will feature a talk on Automated ...
(Date:2/22/2017)... Feb. 22, 2017 Scientists propose in ... organ damage in Gaucher and maybe other lysosomal storage ... lower costs than current therapies. An international ... Center , which also included investigators from the University ... their data Feb. 22. The study was conducted in ...
(Date:2/22/2017)... ... February 22, 2017 , ... ProMIS ... precision treatments for neurodegenerative diseases, today announced it has issued a scientific white ... is one of a series of commentaries from ProMIS’s scientific team offering insight ...
(Date:2/22/2017)... ... ... LabRoots , the leading provider of educational and interactive virtual events ... the launch of a new scholarship for young scientists seeking a degree in any ... open to all high school seniors, 17 years or older; as well as those ...
Breaking Biology Technology:
(Date:1/21/2017)... , Jan 20, 2017 Research and Markets ... Market 2017-2021" report to their offering. ... The global voice recognition biometrics market ... The report covers the present scenario and the ... To calculate the market size, the report considers the revenue generated ...
(Date:1/19/2017)... 19, 2017 Sensory Inc ., ... security for consumer electronics, and i ... and cybersecurity solutions, today announced a global partnership ... institutions worldwide to bolster security of data sensitive ... user authentication platforms they offer, innerCore now offers ...
(Date:1/18/2017)... Minn. , Jan. 18, 2017 ... technology company that supports the entire spectrum of ... has been another record-breaking year for the organization ... market interest in MedNet,s eClinical products and services. ... the tremendous marketplace success of iMedNet ...
Breaking Biology News(10 mins):